Search
Menu
Hamamatsu Corp. - Earth Innovations LB 2/24

Imaging Biomarker for Parkinson’s Clinical Trials Gains EMA Support

Facebook X LinkedIn Email
LONDON and TUCSON, Oct. 13, 2016 — The Critical Path Institute (C-Path) — part of the Critical Path for Parkinson’s Consortium (CPP) — and Parkinson’s U.K. have garnered the support of the European Medicines Agency (EMA) for the use of an imaging biomarker that will help researchers conduct new treatment clinical trials for patients diagnosed with early-stage Parkinson’s disease . The neuroimaging biomarker dopamine transporter imaging system is used as an exploratory biomarker for the early stages of Parkinson’s. CPP's ultimate goal is to achieve biomarker qualification with EMA and...Read full article

Related content from Photonics Media



    Articles


    Products


    Photonics Handbook Articles


    White Papers


    Webinars


    Photonics Dictionary Terms


    Media


    Photonics Buyers' Guide Categories


    Companies
    Published: October 2016
    Glossary
    tomography
    Technique that defocuses activity from surrounding planes by means of the relative motions at the point of interest.
    Research & TechnologyEuropeImagingtomographybioimagingParkinson's diseaseBiophotonicsEuro News

    We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.